CStone breaks up with drugs partner as U.S. rollout stalls
CStone Pharmaceuticals has pulled out of a licensing deal with EQRx for two innovative cancer drugs but holds onto money already received from its partner Key Takeaways: The companies parted…
CStone’s Commercialization Capacity Put to Test With Latest Drug Approval
Company’s four drug approvals in a year will contribute major revenue, but will also challenge CStone’s ability to commercialize its products Key takeaways: Its rollout of four new drugs will…
CStone Finds Tonic in Steady Stream of Drug Approvals, Licensing Deals
Cancer drug specialist reported its first significant revenue in 2020, following a string of milestones capped by a $200 million investment from Pfizer Key takeaways: Strong upfront licensing fees helped…
RELATED ARTICLES
-
Stock disconnect triggers investor exodus from CStone Pharma
2616.HK -
Akeso marks profit milestone with swift rights issue
9926.HK
-
AstraZeneca pays hefty price for Chinese weight-loss drug
AZN.US
-
HBM gets health boost from drug licensing deals
2142.HK
-
Profit setback for Simcere Pharma in novel drugs quest
2096.HK
